{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:24:05Z","timestamp":1790663045202,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the longer\u2010term effects of secukinumab 150 mg on fatigue in patients with ankylosing spondylitis (AS) in the MEASURE 1 study (up to 3\u2009years) and the MEASURE 2 study (up to 2\u2009years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with active AS were randomized to secukinumab or placebo in MEASURE\u20091 (10 mg\/kg intravenous [IV] followed by 150 mg subcutaneous) and MEASURE 2 (150 mg subcutaneous). Patients were naive to treatment with anti\u2013tumor necrosis factor (anti\u2010TNF\u2010naive) therapy or had an inadequate response\/intolerance to anti\u2010TNF therapy (anti\u2010TNF\u2010IR). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT\u2010F) scale. Relationships between fatigue response and baseline characteristics and clinical\/laboratory variables were explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant improvements in FACIT\u2010F scores from baseline were observed with secukinumab across both studies versus placebo at week 16 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Improvements were sustained through week 156 (MEASURE 1) and week 104 (MEASURE 2). Significantly more patients reported fatigue responses (FACIT\u2010F improvement \u22654; observed data) with secukinumab 150 mg than with placebo at week 16 in both MEASURE 1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and MEASURE 2 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Fatigue responses were achieved by 75.6% of patients receiving secukinumab at week 156 (MEASURE 1) and 81.4% at week 104 (MEASURE 2); these results were consistent in patients who were anti\u2010TNF\u2010naive (74.3% and 84.6%, respectively) and anti\u2010TNF\u2010IR (81.3% and 75.0%, respectively). Baseline characteristics did not predict improvement in fatigue consistently. Fatigue responses were moderately to strongly correlated with responses in several clinical measures, including the Assessment of SpondyloArthritis international Society (ASAS) 20%\/40% improvement, ASAS5\/6 responses, the Ankylosing Spondylitis Disease Activity Score with C\u2010reactive protein level, the Bath Ankylosing Spondylitis Disease Activity Index, and the Short Form 36 health questionnaire scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab provided rapid and sustained improvements in fatigue for up to 3\u2009years, regardless of prior anti\u2010TNF exposure.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.24517","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:40Z","timestamp":1606176040000},"page":"759-767","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <scp>Long\u2010Term<\/scp> Results of Two Phase <scp>III<\/scp> Randomized Controlled Trials"],"prefix":"10.1002","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K.","family":"Kvien","sequence":"first","affiliation":[{"name":"Diakonhjemmet Hospital and University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[{"name":"University of Leeds and NIHR Leeds Biomedical Research Centre  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique and Piti\u00e9 Salp\u00eatri\u00e8re Hospital, APHP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine  Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Glostrup, and University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Campus Benjamin Franklin, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin and German Rheumatism Research Centre  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Shete","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gilloteau","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University  Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1928-5"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133793"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art1.10179"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg421"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.07.012"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1249-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S105263"},{"key":"e_1_2_8_11_1","unstructured":"European Medicines Agency. Secukinumab summary of product characteristics. URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/003729\/WC500183129.pdf."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23233"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.1033"},{"key":"e_1_2_8_17_1","first-page":"571","article-title":"Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross\u2010sectional UK study","volume":"35","author":"Espahbodi S","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.3412"},{"key":"e_1_2_8_19_1","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the Adalimumab Trial Evaluating Long\u2010term Safety and Efficacy for Ankylosing Spondylitis (ATLAS)","volume":"35","author":"Revicki DA","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39805"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"e_1_2_8_24_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","volume-title":"SF\u201036 health survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3141"},{"key":"e_1_2_8_27_1","first-page":"50","article-title":"Long\u2010term effects of interleukin\u201017A inhibition with secukinumab in active ankylosing spondylitis: 3\u2010year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22611"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24517","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:59Z","timestamp":1759419119000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/acr.24517"],"URL":"https:\/\/doi.org\/10.1002\/acr.24517","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"2019-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}